New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Home
>
Science Hub
>
New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
April 11, 2024
Hartmut Koeppen et al. The Journal of Pathology
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
You might also be interested by
CellTalk Blog
Tregs in Focus: How a Nobel-Winning Finding is Shaping Clinical Research
October 22, 2025
More infoScientific Publications
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
October 20, 2025
More infoPress Releases
Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
September 24, 2025
More infoCellTalk Blog
B-Cell Populations in Focus: A New Flow Cytometry Assay for Increased Sensitivity in Autoimmune Research
September 19, 2025
Flow Cytometry
More info